A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles

Frontiers in Microbiology

Volumn 6, Issue JUL, 2015, Pages

  Leitner, Deborah R ^a   Lichtenegger, Sabine ^a   Temel, Philipp ^a   Zingl, Franz G ^a   Ratzberger, Desiree ^a   Roier, Sandro ^a   Schild Prüfert, Kristina ^a   Feichter, Sandra ^a   Reidl, Joachim ^a   Schild, Stefan ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHOLERA TOXIN B SUBUNIT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE ANTIGEN; TRICHLOROACETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACID PRECIPITATION; ADULT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL FLAGELLUM; CHOLERA; CHROMOSOME ISOLATION; CONTROLLED STUDY; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOGENICITY; INFANT; LIMIT OF DETECTION; MEMBRANE VESICLE; MOUSE; NEWBORN; NONHUMAN; OUTER MEMBRANE VESICLE; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN PURIFICATION; VACCINATION; VIBRIO CHOLERAE;

ESCHERICHIA COLI; OAT MOSAIC VIRUS; VIBRIO CHOLERAE;

EID: 84938925680     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00823     Document Type: Article

References (79)

1. Ahren, C.M., and Svennerholm, A.M. (1982). Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect Immun 38, 74-79.
2. Baker, K.K., Levine, M.M., Morison, J., Phillips, A., and Barry, E.M. (2009). CfaE tip mutations in enterotoxigenic Escherichia coli CFA/I fimbriae define critical human intestinal binding sites. Cell Microbiol 11, 742-754.
3. Beveridge, T.J. (1999). Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 181, 4725-4733.
4. Bishop, A.L., and Camilli, A. (2011). Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines 10, 79-94.
5. Bishop, A.L., Schild, S., Patimalla, B., Klein, B., and Camilli, A. (2010). Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect. Immun. 78, 4402-4420. doi: IAI.00398-10 [pii]10.1128/IAI.00398-10.
6. Bishop, A.L., Tarique, A.A., Patimalla, B., Calderwood, S.B., Qadri, F., and Camilli, A. (2012). Immunization of mice with Vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission. J Infect Dis 205, 412-421.
7. Bryce, J., Boschi-Pinto, C., Shibuya, K., and Black, R.E. (2005). WHO estimates of the causes of death in children. Lancet 365, 1147-1152.
8. Byrd, W., and Boedeker, E.C. (2013). Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT induced fluid accumulation. Vet Immunol Immunopathol 152, 57-67. doi: 10.1016/j.vetimm.2012.10.001.
9. Chatterjee, D., and Chaudhuri, K. (2011). Association of cholera toxin with Vibrio cholerae outer membrane vesicles which are internalized by human intestinal epithelial cells. FEBS Lett. 585, 1357-1362. doi: S0014-5793(11)00264-X [pii]10.1016/j.febslet.2011.04.017.
10. Cheng, E., Cardenas-Freytag, L., and Clements, J.D. (1999). The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18, 38-49.
11. Clemens, J.D., Sack, D.A., Chakraborty, J., Rao, M.R., Ahmed, F., Harris, J.R., Van Loon, F., Khan, M.R., Yunis, M., Huda, S., and et al. (1990). Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 8, 469-472.
12. Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Neogy, P.K., Stanton, B., Huda, N., Khan, M.U., Kay, B.A., Khan, M.R., and et al. (1988). Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158, 372-377.
13. Clements, J.D., and Finkelstein, R.A. (1978). Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun 21, 1036-1039.
14. Cumberland, S. (2009). An old enemy returns. Bulletin of the World Health Organization 87, 85-86.
15. Darsley, M.J., Chakraborty, S., Denearing, B., Sack, D.A., Feller, A., Buchwaldt, C., Bourgeois, A.L., Walker, R., and Harro, C.D. (2012). The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19, 1921-1931. doi: 10.1128/CVI.00364-12.
16. Dhungyel, O., Hunter, J., and Whittington, R. (2014). Footrot vaccines and vaccination. Vaccine 32, 3139-3146. doi: 10.1016/j.vaccine.2014.04.006.
17. Donnenberg, M.S., and Kaper, J.B. (1991). Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59, 4310-4317.
18. Ellis, T.N., and Kuehn, M.J. (2010). Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol. Mol. Biol. Rev. 74, 81-94. doi: 74/1/81 [pii]10.1128/MMBR.00031-09.
19. Evans, D.G., Evans, D.J., Jr., and Tjoa, W. (1977). Hemagglutination of human group A erythrocytes by enterotoxigenic Escherichia coli isolated from adults with diarrhea: correlation with colonization factor. Infect Immun 18, 330-337.
20. Evans, D.J., Jr., and Evans, D.G. (1973). Three characteristics associated with enterotoxigenic Escherichia coli isolated from man. Infect Immun 8, 322-328.
21. Faruque, S.M., Albert, M.J., and Mekalanos, J.J. (1998). Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol. and Mol. Biol. Rev. 62, 1301-1314.
22. Fengler, V.H., Boritsch, E.C., Tutz, S., Seper, A., Ebner, H., Roier, S., Schild, S., and Reidl, J. (2012). Disulfide bond formation and ToxR activity in Vibrio cholerae. PLoS One 7, e47756.
23. Fisseha, M., Chen, P., Brandt, B., Kijek, T., Moran, E., and Zollinger, W. (2005). Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 73, 4070-4080.
24. Fleckenstein, J., Sheikh, A., and Qadri, F. (2014). Novel antigens for enterotoxigenic Escherichia coli vaccines. Expert Rev Vaccines 13, 631-639. doi: 10.1586/14760584.2014.905745.
25. Fredriksen, J.H., Rosenqvist, E., Wedege, E., Bryn, K., Bjune, G., Froholm, L.O., Lindbak, A.K., Mogster, B., Namork, E., Rye, U., and et al. (1991). Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14, 67-79; discussion 79-80.
26. Freedman, D.J., Tacket, C.O., Delehanty, A., Maneval, D.R., Nataro, J., and Crabb, J.H. (1998). Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis 177, 662-667.
27. Gankema, H., Wensink, J., Guinee, P.A., Jansen, W.H., and Witholt, B. (1980). Some characteristics of the outer membrane material released by growing enterotoxigenic Escherichia coli. Infect Immun 29, 704-713.
28. Goldhar, J., Zilberberg, A., and Ofek, I. (1986). Infant mouse model of adherence and colonization of intestinal tissues by enterotoxigenic strains of Escherichia coli isolated from humans. Infect Immun 52, 205-208.
29. Haiko, J., and Westerlund-Wikstrom, B. (2013). The role of the bacterial flagellum in adhesion and virulence. Biology (Basel) 2, 1242-1267. doi: 10.3390/biology2041242.
30. Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166, 557-580.
31. Harris, J.B., Larocque, R.C., Qadri, F., Ryan, E.T., and Calderwood, S.B. (2012). Cholera. Lancet 379, 2466-2476.
32. Harro, C., Sack, D., Bourgeois, A.L., Walker, R., Denearing, B., Feller, A., Chakraborty, S., Buchwaldt, C., and Darsley, M.J. (2011). A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol 18, 2118-2127. doi: 10.1128/CVI.05342-11.
33. Holmgren, J., Bourgeois, L., Carlin, N., Clements, J., Gustafsson, B., Lundgren, A., Nygren, E., Tobias, J., Walker, R., and Svennerholm, A.M. (2013). Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 31, 2457-2464. doi: 10.1016/j.vaccine.2013.03.027.
34. Horstman, A.L., and Kuehn, M.J. (2000). Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. J Biol Chem 275, 12489-12496.
35. Horstman, A.L., and Kuehn, M.J. (2002). Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway. J Biol Chem 277, 32538-32545.
36. Horton, R.M., Hunt, H.D., Ho, S.N., Pullen, J.K., and Pease, L.R. (1989). Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77, 61-68.
37. Iwanaga, M., and Yamamoto, K. (1985). New medium for the production of cholera toxin by Vibrio cholerae O1 biotype El Tor. J Clin Microbiol 22, 405-408.
38. Iwanaga, M., Yamamoto, K., Higa, N., Ichinose, Y., Nakasone, N., and Tanabe, M. (1986). Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol. Immunol. 30, 1075-1083.
39. Jertborn, M., Svennerholm, A.M., and Holmgren, J. (1992). Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10, 130-132.
40. Jertborn, M., Svennerholm, A.M., and Holmgren, J. (1993). Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 11, 1007-1012.
41. Jertborn, M., Svennerholm, A.M., and Holmgren, J. (1994). Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12, 1078-1082.
42. Kang, D., Gho, Y.S., Suh, M., and Kang, C. (2002). Highly sensitive and fast protein detection with coomassie brilliant blue in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Bull. Kor. Chem. Soc. 23, 1511-1512.
43. Kesty, N.C., Mason, K.M., Reedy, M., Miller, S.E., and Kuehn, M.J. (2004). Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells. Embo J 23, 4538-4549.
44. Koch, R. (1884). An address on cholera and its bacillus. Br. Med. J. 2, 403-407.
45. Leitner, D.R., Feichter, S., Schild-Prufert, K., Rechberger, G.N., Reidl, J., and Schild, S. (2013). Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen. Infect Immun 81, 2379-2393. doi: IAI.01382-12 [pii]10.1128/IAI.01382-12.
46. Levine, M.M. (2006). Enteric infections and the vaccines to counter them: future directions. Vaccine 24, 3865-3873.
47. Lewis, D.J., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., Del Giudice, G., and Rappuoli, R. (2009). Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999.
48. Lundgren, A., Leach, S., Tobias, J., Carlin, N., Gustafsson, B., Jertborn, M., Bourgeois, L., Walker, R., Holmgren, J., and Svennerholm, A.M. (2013). Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine 31, 1163-1170. doi: 10.1016/j.vaccine.2012.12.063.
49. Miller, V.L., Dirita, V.J., and Mekalanos, J.J. (1989). Identification of toxS, a regulatory gene whose product enhances toxR-mediated activation of the cholera toxin promoter. J Bacteriol 171, 1288-1293.
50. Miller, V.L., and Mekalanos, J.J. (1988). A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 170, 2575-2583.
51. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R.T., Linder, T., Spyr, C., and Steffen, R. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350, 896-903. doi: 10.1056/NEJMoa030595.
52. Oster, P., Lennon, D., O'hallahan, J., Mulholland, K., Reid, S., and Martin, D. (2005). MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191-2196.
53. Peltola, H., Siitonen, A., Kyronseppa, H., Simula, I., Mattila, L., Oksanen, P., Kataja, M.J., and Cadoz, M. (1991). Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338, 1285-1289.
54. Raetz, C.R., and Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annu Rev Biochem 71, 635-700.
55. Rao, M.R., Abu-Elyazeed, R., Savarino, S.J., Naficy, A.B., Wierzba, T.F., Abdel-Messih, I., Shaheen, H., Frenck, R.W., Jr., Svennerholm, A.M., and Clemens, J.D. (2003). High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol 41, 4862-4864.
56. Roier, S., Fenninger, J.C., Leitner, D.R., Rechberger, G.N., Reidl, J., and Schild, S. (2013). Immunogenicity of Pasteurella multocida and Mannheimia haemolytica outer membrane vesicles. Int J Med Microbiol 303, 247-256. doi: S1438-4221(13)00065-9 [pii]10.1016/j.ijmm.2013.05.001.
57. Roier, S., Leitner, D.R., Iwashkiw, J., Schild-Prufert, K., Feldman, M.F., Krohne, G., Reidl, J., and Schild, S. (2012). Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS One 7, e42664.
58. Roy, K., Bartels, S., Qadri, F., and Fleckenstein, J.M. (2010). Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins. Infect Immun 78, 3027-3035.
59. Roy, K., Hamilton, D., Ostmann, M.M., and Fleckenstein, J.M. (2009a). Vaccination with EtpA glycoprotein or flagellin protects against colonization with enterotoxigenic Escherichia coli in a murine model. Vaccine 27, 4601-4608.
60. Roy, K., Hamilton, D.J., Munson, G.P., and Fleckenstein, J.M. (2011). Outer membrane vesicles induce immune responses to virulence proteins and protect against colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 18, 1803-1808.
61. Roy, K., Hilliard, G.M., Hamilton, D.J., Luo, J., Ostmann, M.M., and Fleckenstein, J.M. (2009b). Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Nature 457, 594-598. doi: 10.1038/nature07568.
62. Sack, D.A., Huda, S., Neogi, P.K., Daniel, R.R., and Spira, W.M. (1980). Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin. J Clin Microbiol 11, 35-40.
63. Sanchez, J., and Holmgren, J. (2005). Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 17, 388-398.
64. Schild, S., Nelson, E.J., Bishop, A.L., and Camilli, A. (2009). Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 77, 472-484.
65. Schild, S., Nelson, E.J., and Camilli, A. (2008). Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 76, 4554-4563.
66. Sherlock, O., Schembri, M.A., Reisner, A., and Klemm, P. (2004). Novel roles for the AIDA adhesin from diarrheagenic Escherichia coli: cell aggregation and biofilm formation. J Bacteriol 186, 8058-8065. doi: 10.1128/JB.186.23.8058-8065.2004.
67. Sixma, T.K., Pronk, S.E., Kalk, K.H., Wartna, E.S., Van Zanten, B.A., Witholt, B., and Hol, W.G. (1991). Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 351, 371-377. doi: 10.1038/351371a0.
68. Somerville, J.E., Jr., Cassiano, L., Bainbridge, B., Cunningham, M.D., and Darveau, R.P. (1996). A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J Clin Invest 97, 359-365.
69. Svennerholm, A.M. (2011). From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J Med Res 133, 188-196.
70. Svennerholm, A.M., and Lundgren, A. (2012). Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines 11, 495-507. doi: 10.1586/erv.12.12.
71. Tacket, C.O., Losonsky, G., Link, H., Hoang, Y., Guesry, P., Hilpert, H., and Levine, M.M. (1988). Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 318, 1240-1243. doi: 10.1056/NEJM198805123181904.
72. Tobias, J., Holmgren, J., Hellman, M., Nygren, E., Lebens, M., and Svennerholm, A.M. (2010a). Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria. Vaccine 28, 6977-6984.
73. Tobias, J., Svennerholm, A.M., Carlin, N.I., Lebens, M., and Holmgren, J. (2011). Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. Vaccine 29, 8863-8869. doi: 10.1016/j.vaccine.2011.09.096.
74. Tobias, J., Svennerholm, A.M., Holmgren, J., and Lebens, M. (2010b). Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines. Appl Microbiol Biotechnol 87, 1355-1365.
75. Turner, A.K., Stephens, J.C., Beavis, J.C., Greenwood, J., Gewert, C., Randall, R., Freeman, D., and Darsley, M.J. (2011). Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. Clin Vaccine Immunol 18, 2128-2135. doi: 10.1128/CVI.05345-11.
76. Van Der Ley, P., Steeghs, L., Hamstra, H.J., Ten Hove, J., Zomer, B., and Van Alphen, L. (2001). Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69, 5981-5990.
77. Van Der Ley, P., and Van Den Dobbelsteen, G. (2011). Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 7, 886-890.
78. Who (2006). Furture directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Weekly epidemiological record, http://www.who.int/wer 11, 97-104.
79. Who (2010). Cholera vaccines: WHO position paper. Weekly epidemiological record, http://www.who.int/wer 13, 117-128.